Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - An antipsychotic agent used in schizophrenia. [PubChem] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Glazer WM: Does loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry. 1999;60 Suppl 10:42-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10340686 # Cheung SW, Tang SW, Remington G: Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography. J Chromatogr. 1991 Mar 8;564(1):213-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1860915 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - For the management of the manifestations of psychotic disorders such as schizophrenia (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Loxapine is a dopamine antagonist, and also a serotonin 5-HT2 blocker. The exact mode of action of Loxapine has not been established, however changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such manifestations of tranquilization as calming effects and suppression of aggressive behavior. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - Metabolites are excreted in the urine in the form of conjugates and in the feces unconjugated. (en)
|
http://linked.open.../drugbank/synonym
| - Loxapine (en)
- Cloxazepine (en)
- 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (en)
- Loxapina (en)
- Loxapinum (en)
- oxilapine (en)
|
http://linked.open...drugbank/toxicity
| - LD<sub>50</sub>=65 mg/kg (Orally in mice) (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Take with food to reduce irritation. Avoid alcohol. (en)
|
http://linked.open...ynthesisReference
| - U.S. Patents 3,412,193; 3,546,226. (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Systemic bioavailability of the parent drug was only about one third that after an equivalent intramuscular dose (25 mg base) in male volunteers (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...gbank/containedIn
| |
http://linked.open...k/Bioavailability
| |